Stephen J. Wood

发表

Parkinson's Disease-associated α-Synuclein Is More Fibrillogenic than β- and γ-Synuclein and Cannot Cross-seed Its Homologs*

M. Citron, D. Anafi, L. Narhi, 2000, The Journal of Biological Chemistry.

From fragment screening to in vivo efficacy: optimization of a series of 2-aminoquinolines as potent inhibitors of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1).

Yuan Cheng, Thomas Nixey, Yi Luo, 2011, Journal of medicinal chemistry.

alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease.

M. Citron, J. Wypych, S. Steavenson, 1999, The Journal of biological chemistry.

Effect of LXR/RXR agonism on brain and CSF Aβ40 levels in rats

Paul H. Wen, Songli Wang, Stephen J. Wood, 2016, F1000Research.

Translational Approaches in Alzheimer’s Disease

Gabriel Vargas, Stephen Wood, Gabriel A Vargas, 2016 .

Structure- and property-based design of aminooxazoline xanthenes as selective, orally efficacious, and CNS penetrable BACE inhibitors for the treatment of Alzheimer's disease.

R. Wahl, A. Cheng, R. Fremeau, 2012, Journal of medicinal chemistry.

Inhibitors of β-site amyloid precursor protein cleaving enzyme (BACE1): identification of (S)-7-(2-fluoropyridin-3-yl)-3-((3-methyloxetan-3-yl)ethynyl)-5'H-spiro[chromeno[2,3-b]pyridine-5,4'-oxazol]-2'-amine (AMG-8718).

R. Wahl, A. Cheng, R. Fremeau, 2014, Journal of medicinal chemistry.

Design and preparation of a potent series of hydroxyethylamine containing β-secretase inhibitors that demonstrate robust reduction of central β-amyloid.

Yuan Cheng, Wenge Zhong, Michael D Bartberger, 2012, Journal of medicinal chemistry.

The Discovery of AM-6494: A Potent and Orally Efficacious β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor with in vivo Selectivity over BACE2.

D. Whittington, Michael G. Johnson, M. Bartberger, 2020, Journal of medicinal chemistry.

Development of 2-aminooxazoline 3-azaxanthenes as orally efficacious β-secretase inhibitors for the potential treatment of Alzheimer's disease.

S. Hitchcock, A. Cheng, Yuan Cheng, 2015, Bioorganic & medicinal chemistry letters.

An Orally Available BACE1 Inhibitor That Affords Robust CNS Aβ Reduction without Cardiovascular Liabilities.

Xiao Mei Zheng, R. Wahl, S. Hitchcock, 2015, ACS medicinal chemistry letters.

Lead optimization and modulation of hERG activity in a series of aminooxazoline xanthene β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors.

Xiao Mei Zheng, R. Wahl, A. Cheng, 2014, Journal of medicinal chemistry.

Design and synthesis of potent, orally efficacious hydroxyethylamine derived β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors.

R. Wahl, S. Hitchcock, Yuan Cheng, 2012, Journal of medicinal chemistry.

A Potent and Orally Efficacious, Hydroxyethylamine-Based Inhibitor of β-Secretase.

Yuan Cheng, Yi Luo, Wenge Zhong, 2012, ACS medicinal chemistry letters.

Hydroxyethylamine-based inhibitors of BACE1: P₁-P₃ macrocyclization can improve potency, selectivity, and cell activity.

R. Wahl, S. Hitchcock, M. Citron, 2013, Bioorganic & medicinal chemistry letters.

Discovery of 2-methylpyridine-based biaryl amides as γ-secretase modulators for the treatment of Alzheimer's disease.

Shannon Rumfelt, N. Chen, S. Hitchcock, 2013, Bioorganic & medicinal chemistry letters.

Development of 2-aminooxazoline 3-azaxanthene β-amyloid cleaving enzyme (BACE) inhibitors with improved selectivity against Cathepsin D.

Yuan Cheng, D. Whittington, M. Bartberger, 2017, MedChemComm.

Establishing the Relationship between In Vitro Potency, Pharmacokinetic, and Pharmacodynamic Parameters in a Series of Orally Available, Hydroxyethylamine-Derived β-Secretase Inhibitors

S. Hitchcock, M. Citron, S. Babu-Khan, 2012, Journal of Pharmacology and Experimental Therapeutics.

The development of a structurally distinct series of BACE1 inhibitors via the (Z)-fluoro-olefin amide bioisosteric replacement.

N. Chen, D. Whittington, M. Bartberger, 2020, Bioorganic & medicinal chemistry letters.